Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty

Piotr Biega110 enrolled

Overview

This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.

Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures.

Study Type

OBSERVATIONAL

Enrollment

110

Conditions

Metastases to Bone

Interventions

Tranexamic acid injectionDRUG

Tranexamic acid were administered at a dose of 1.0 g during the induction of anaesthesia and immediately after surgery.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patological fracture * Arthroplasty using a modular prosthesis. Exclusion Criteria: * threatened fracture * intraoperative blood transfusion * fracture fixation

Locations (1)

SzSPOO Brzozów

Brzozów, Podkarpackie Voivodeship, Poland

Outcomes

Primary Outcomes

Number of participants who require a blood transfusion.

Need of blood transfusion

Time frame: During Hospitalization (up to day 10)

Secondary Outcomes

Estimeted blood lost after surgery.

Gross total blood loss was estimated utilizing the formula PBV × (Hctpre- Hctpost)/Hcta

Time frame: During Hospitalization (up to day 3)

Number of participants with embolic complication.

Yes or No

Time frame: During Hospitalization (up to day 10)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.